FindMyKOL
Clinical trialNCT02180698CompletedPhase 1Interventional

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

NCT02180698 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it is completed. It studies TLR4 Agonist GLA-SE in Stage III Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma. The registry lists an enrollment of 16 participants at 1 site in 1 country. The registry lists a start date of 17 Nov 2014 and a primary completion date of 7 Oct 2016. One of its registered investigators has a FindMyKOL profile.

SponsorFred Hutchinson Cancer Center →Enrollment16Stage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02180698
FieldValue
Registry IDNCT02180698
StatusCompleted
PhasePhase 1
Study typeInterventional trial
Lead sponsorFred Hutchinson Cancer Center
Enrollment16
Registered sites1
Countries1
ConditionsStage III Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma
DrugsTLR4 Agonist GLA-SE
Start17 Nov 2014
Primary completion7 Oct 2016
Study completion7 Oct 2016
Last update posted6 Nov 2019

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This pilot phase I clinical trial studies the side effects and best dose of toll-like receptor 4 (TLR4) agonist glucopyranosyl lipid A (GLA)-stable-emulsion (SE) when given together with radiation therapy in treating patients with soft tissue sarcoma that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable). TLR4 agonist GLA-SE may stimulate the immune system to kill sarcoma cells. Radiation therapy uses high energy x rays to kill tumor cells. Giving TLR4 agonist GLA-SE with radiation therapy may be a better treatment to treat sarcoma that cannot be removed by surgery.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Washington, United States1 site
  • Fred Hutch/university of Washington Cancer Consortium

    Seattle

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 1 siteWA1MontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

TLR4 Agonist GLA-SE
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02180698

Each answer restates registry values shown on this page.

What is NCT02180698?

NCT02180698 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies TLR4 Agonist GLA-SE in Stage III Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma.

Who leads NCT02180698?

The registry names Seth Pollack (principal investigator, Fred Hutch/University of Washington Cancer Consortium) as the overall official.

Where does NCT02180698 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02180698 study?

The registered drug and biological interventions are TLR4 Agonist GLA-SE.

When did NCT02180698 end?

The registry lists a primary completion date of 7 Oct 2016 and a study completion date of 7 Oct 2016. The sponsor last updated the record on 6 Nov 2019.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.